Amgen Strengthens US Biomanufacturing with $900M Ohio Investment

Amgen is doubling down on its manufacturing footprint in Ohio, announcing a major $900 million expansion to its Central Ohio facility. The new investment brings the company’s total commitment in the region to more than $1.4 billion and is expected to create 350 additional jobs, raising the total number of new positions to 750.

It’s the latest step in Amgen’s broader strategy to fortify its US-based biomanufacturing capacity, a move that has ripple effects for both the local economy and the global supply of biologic medicines.

What began in 2021 as a plan to build a biomanufacturing facility in Central Ohio has since grown into a significant production site. The facility opened in early 2024, equipped with Amgen’s FLEX manufacturing platform — a modular, scalable system designed to accelerate production timelines and improve adaptability across biologics.

With the new 2025 expansion, Amgen is building on this foundation to meet rising demand for complex biologic therapies, especially in strategically located regions with access to skilled workforces.

XTALKS WEBINAR: Enabling Efficient Biomanufacturing Through Process Intensification

Live and On-Demand: Tuesday, May 27, 2025, at 10am EDT (4pm CEST/EU-Central)

Register for this free webinar to gain actionable guidance on leveraging process intensification to future-proof upstream strategies — and see how the right CDMO partnership can make all the difference.

The latest announcement follows a series of significant investments by Amgen across North America.

In late 2024, the company unveiled plans to invest $1 billion in a new manufacturing site in Holly Springs, North Carolina, projected to create 370 jobs. Like the Ohio facility, the Holly Springs plant is built around next-generation manufacturing platforms that allow faster scaling and greater adaptability as therapeutic pipelines grow.

Global demand for biologic therapies has been on the rise — likely to more than double by 2035, growing from $450.2 billion in 2025 to over $1 trillion, driven by increasing prevalence of cancer, autoimmune conditions and next-gen therapies. Among the leading biotech forces, Amgen has always been a key player in this field.

Beyond these major site developments, Amgen’s continued expansion activity signals a broader industry movement to bring biologic drug production closer to the patients who need them. While Amgen strengthens its US base, other pharmaceutical leaders are also scaling biologics manufacturing across the country.

Merck recently announced a $1 billion investment to build a new facility in Delaware — its first in-house US site for producing the cancer immunotherapy Keytruda (pembrolizumab) — creating 500 full-time jobs and thousands of construction roles.

Meanwhile, Regeneron is expanding its US manufacturing capacity through a $3 billion partnership with FUJIFILM Diosynth Biotechnologies in North Carolina and a broader $7 billion infrastructure push that includes multiple New York sites.

Amgen’s expansion efforts are among a slew of coordinated moves by biotech and pharma leaders to reinforce domestic production capabilities and strengthen long-term supply chain resilience.

If you want your company to be featured on Xtalks.com, please email [email protected].